Inhibition of miR-34a could alleviate steatosis and suppress lipid accumulation in the mouse NAFLD model by specifically targeting hepatic PPARα and SIRT1 [10]. Here, SIRT1 is linked to metabolic dysfunction-associated steatotic liver disease.